SAN CARLOS, Calif. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement

Tumor Infiltrating Lymphocyte (TIL) Cell Therapy   in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Update Conference Call

21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Conference Call and Webcast on Saturday, November 13 at 5:30pm ET SAN CARLOS, Calif. , and WASHINGTON , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iovance

TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer 21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint  Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN

SAN CARLOS, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in November: Festival of

Advancing TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL,

SAN CARLOS, Calif. , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 4, 2021 .

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif. , Oct.

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab  in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune Checkpoint  Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) Additional Posters Highlight Potential

Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Cell Therapies for Thousands of Cancer Patients Annually SAN CARLOS, Calif. , Sept.

First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and

Expanding Leadership for TIL Cell Therapy in Solid Tumors SAN CARLOS, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and

SAN CARLOS, Calif. , July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021 .

SAN CARLOS, Calif. , June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies   Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif.

Median Duration of Response (DOR) Not Reached at 33.1 Months  of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET Today SAN CARLOS, Calif.

86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease ASCO Update Conference Call and

SAN CARLOS, Calif. , June 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in June:

86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study At Median of 28-Month Study Follow up, Median Duration of Response (DOR) not reached in Cohort 2 in post-PD1 Advanced

SAN CARLOS, Calif. , May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up C-144-01 Study Contributes to Advancement in TIL Therapy Using Centrally  Standardized Manufacturing, Allowing for Broadened Patient Access SAN CARLOS, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics,

Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors SAN CARLOS, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and

SAN CARLOS, Calif. , May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in May: Truist

Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- Iovance

SAN CARLOS, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021 .

Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif. , April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.

SAN CARLOS, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky , Ph.D., as Chief Operating Officer, effective today. Dr.

SAN CARLOS, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579) in

SAN CARLOS, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:

Advancing First-in-Class TIL Cell Therapy for Solid Tumors SAN CARLOS, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and

SAN CARLOS, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 .

SAN CARLOS, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences: B.